Industry News

• Hologic's reports positive data from NovaSure® endometrial ablation system in new study  Hologic announced in a new study that women treated with NovaSure® endometrial ablation reported a higher one-year amenorrhearate, better QOL post-procedure, and greater satisfaction than women treated with Minerva endometrial ablation. The study was published in the Journal of Women's Health.
  April 19, 2018  
• Rigel announces pricing of public offering of common stock  Rigel Pharma announced pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public. Gross proceeds are expected to be $62.4 million. The offering is expected to close April 24, 2018.
  April 19, 2018  
• Scientists identify 170 potential lung cancer drug targets using unique cellular library  After testing more than 200,000 chemical compounds, Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer. The 5-year project set out to identify therapeutic targets for non-small cell lung cancer.
  April 19, 2018  
• The Rivkin Center awards $1.185 million in ovarian cancer research grants  The Rivkin Center for Ovarian Cancer announced it has awarded $1.185 million in ovarian cancer research grants for 2018. The amount funded was a 10% increase from the previous year. Grant recipients include researchers from the U.S., Italy, Australia, and Israel.
  April 19, 2018  
• OpGen completes rapid testing clinical trial in Colombia and expands operations  OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification and treatment of bacteremia and fungemia in hospital intensive care units in Colombia.
  April 19, 2018  
• Argos Therapeutics to discontinue the ADAPT trial  Argos Therapeutics reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for treatment of newly diagnosed metastatic renal cell carcinoma.
  April 19, 2018  
• VBI Vaccines announces completion of enrollment in PROTECT phase 3 clinical study  VBI Vaccines announced completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation hepatitis B vaccine. More than 1,600 adults have now been enrolled in the PROTECT study at 27 sites.
  April 19, 2018  
• Capricor announces positive results from new pre-clinical study of CAP-1002  Capricor Therapeutics announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase in exercise performance in a disease model of Duchenne muscular dystrophy, the mdx mouse.
  April 19, 2018  
• Teva and Procter & Gamble have agreed to terminate PGT Healthcare partnership  Teva and Procter & Gamble have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC medicines. The separation is planned to take effect July 1, 2018.
  April 19, 2018  
• Sharing more than a common border: U.S. and Canadian approaches to biospecimens  U.S. and Canadian regulations may be becoming more consistent with regard to research that involves the use of biospecimens. Recent changes proposed to the regulations governing research in Canada may provide a mechanism similar to the Broad Consent provision of the new Common Rule in the U.S.
  April 19, 2018  

   (next 10 articles)